MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in …

2023年5月19日 · MAFLD and CVD are two highly prevalent global public health challenges. While the proposed change in nomenclature from NAFLD to MAFLD is new, the available evidence …

2023年5月16日 · MAFLD is associated with an increased risk of cardiovascular diseases (CVD), including hypertension, atherosclerosis, cardiomyopathies, and chronic kidney disease. While …

2025年3月1日 · Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is a newly proposed concept that shares common metabolic risk factors with cardiovascular disease. …

5 天之前 · A total of 340,998 participants in the UK Biobank study were included. Multivariable Cox proportional hazards models were used to estimate the effect of MAFLD and MASLD on …

In terms of coronary risk surrogates, the MAFLD or NAFLD population had a significantly higher proportion of subjects with CACS > 100, coronary artery disease, higher grade of coronary …

2023年10月30日 · 摘要: 代谢相关脂肪性肝病（MAFLD）是全球范围内常见的慢性肝病，影响全球超过四分之一的成年人口。 MAFLD特征是肝脏脂肪变性和代谢紊乱共存。 作为一种代谢功能 …

代谢功能障碍相关脂肪性肝病(metabolic dysfunction-associated fatty liver disease, MAFLD)是最普遍的慢性肝病之一,但MAFLD 患者死于心血管疾病(cardiovascular disease, CVD)的频率高于 …

glp－1ra可用于治疗患有mafld的t2dm患者，在改善cvd预后方面具有公认的疗效，它可降低主要cvd不良事件、降低cvd病死率和全因死亡风险，且无明显的安全性问题。

recent studies have shown that MAFLD is a predictor of adverse CVD outcomes, independent of traditional risk fac-tors [10]. Increasing evidence now supports a link between MAFLD and …